Yahoo Poland Wyszukiwanie w Internecie

Search results

1. www.nejm.org › doi › fullOnce-Weekly Semaglutide in Adults with Overweight or Obesity

   www.nejm.org › doi › full

   10 lut 2021 · In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight. (Funded by...

2. www.forbes.com › health › weight-lossSemaglutide For Weight Loss: Is It Worth It? – Forbes Health

   www.forbes.com › health › weight-loss

   • Zapisane w pamięci cache

   3 sie 2023 · While the drug—commonly known by brand names such as Ozempic and Wegovy — helps reduce blood glucose to normal levels, it also slows the passage of food through the stomach and reduces appetite,...

3. www.thelancet.com › journals › landiaSemaglutide: weighing up the benefits and risks

   www.thelancet.com › journals › landia

   Semaglutide, a GLP-1 receptor analogue, was originally intended to treat diabetes (brand name Ozempic) but has found a new use resulting in rocketing popularity (Wegovy). Upon discovering that those using the medication encountered substantial weight loss, it is now used by large numbers of people for that purpose alone.

4. www.nature.com › articles › s41591/024/02996-7Long-term weight loss effects of semaglutide in obesity without...

   www.nature.com › articles › s41591/024/02996-7

   13 maj 2024 · With semaglutide, lower BMI was associated with less percentage weight loss, and women lost more weight on average than men (−11.1% versus −7.5% treatment difference from placebo); however, in...

5. diet.mayoclinic.org › us › blogHow does semaglutide work? - Mayo Clinic Diet

   diet.mayoclinic.org › us › blog

   • Zapisane w pamięci cache

   Semaglutide, the active ingredient in Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist that has been approved by the Food and Drug Administration (FDA) for weight loss in adults with overweight or obesity.

6. www.bmj.com › content › 385Semaglutide may provide sustained weight loss for at least ... -...

   www.bmj.com › content › 385

   • Zapisane w pamięci cache

   16 maj 2024 · A new analysis of data from Novo Nordisk’s Select trial indicates that semaglutide (marketed as Wegovy) can enable patients who are overweight or obese to “achieve clinically meaningful weight loss” for at least four years, with fewer serious adverse events than placebo. 1 The analysis, conducted by the manufacturer and published in Nature Medic...

7. www.nature.com › articles › s41591/022/02026-4Two-year effects of semaglutide in adults with overweight or...

   www.nature.com › articles › s41591/022/02026-4

   10 paź 2022 · Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Article Open access 13 May 2024. Weight loss and cardiovascular disease risk outcomes of...